X4 Pharmaceuticals Inc (XFOR) - Net Assets
Based on the latest financial reports, X4 Pharmaceuticals Inc (XFOR) has net assets worth $155.45 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($253.06 Million) and total liabilities ($97.61 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check X4 Pharmaceuticals Inc strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $155.45 Million |
| % of Total Assets | 61.43% |
| Annual Growth Rate | N/A |
| 5-Year Change | 189.22% |
| 10-Year Change | N/A |
| Growth Volatility | 289.51 |
X4 Pharmaceuticals Inc - Net Assets Trend (2015–2025)
This chart illustrates how X4 Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see X4 Pharmaceuticals Inc (XFOR) total market value.
Annual Net Assets for X4 Pharmaceuticals Inc (2015–2025)
The table below shows the annual net assets of X4 Pharmaceuticals Inc from 2015 to 2025. Also explore net asset momentum of X4 Pharmaceuticals Inc to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $186.29 Million | +741.08% |
| 2024-12-31 | $22.15 Million | -56.65% |
| 2023-12-31 | $51.10 Million | -30.99% |
| 2022-12-31 | $74.05 Million | +14.96% |
| 2021-12-31 | $64.41 Million | -11.52% |
| 2020-12-31 | $72.80 Million | -43.66% |
| 2019-12-31 | $129.22 Million | +498.24% |
| 2018-12-31 | $21.60 Million | -63.21% |
| 2017-12-31 | $58.71 Million | +451.03% |
| 2016-12-31 | $-16.72 Million | -282.35% |
| 2015-12-31 | $-4.37 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to X4 Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 55914100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $91.00K | 0.05% |
| Other Comprehensive Income | $-109.00K | -0.06% |
| Other Components | $780.86 Million | 419.16% |
| Total Equity | $186.29 Million | 100.00% |
X4 Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of X4 Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
YC Inox Co Ltd
TW:2034
|
$347.22 Million |
|
Spear REIT Ltd
JSE:SEA
|
$347.28 Million |
|
Village Farms International Inc
NASDAQ:VFF
|
$347.29 Million |
|
Hangzhou Coco Healthcare Products Co.Ltd.
SHE:301009
|
$347.29 Million |
|
Paz Corp
SN:PAZ
|
$347.01 Million |
|
Shanxi Huayang New Material Co Ltd
SHG:600281
|
$347.01 Million |
|
HeidelbergCement India Limited
NSE:HEIDELBERG
|
$346.95 Million |
|
Microtek International Inc
TW:2305
|
$346.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in X4 Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 22,149,000 to 186,290,000, a change of 164,141,000 (741.1%).
- Net loss of 79,199,000 reduced equity.
- New share issuances of 238,530,000 increased equity.
- Other comprehensive income increased equity by 13,000.
- Other factors increased equity by 4,797,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-79.20 Million | -42.51% |
| Share Issuances | $238.53 Million | +128.04% |
| Other Comprehensive Income | $13.00K | +0.01% |
| Other Changes | $4.80 Million | +2.58% |
| Total Change | $- | 741.08% |
Book Value vs Market Value Analysis
This analysis compares X4 Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.79x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $-418.52 | $3.50 | x |
| 2016-12-31 | $-1263.62 | $3.50 | x |
| 2017-12-31 | $30752.75 | $3.50 | x |
| 2018-12-31 | $47.06 | $3.50 | x |
| 2019-12-31 | $336.22 | $3.50 | x |
| 2020-12-31 | $108.78 | $3.50 | x |
| 2021-12-31 | $75.05 | $3.50 | x |
| 2022-12-31 | $34.97 | $3.50 | x |
| 2023-12-31 | $8.62 | $3.50 | x |
| 2024-12-31 | $3.30 | $3.50 | x |
| 2025-12-31 | $4.40 | $3.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently X4 Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -42.51%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -225.55%
- • Asset Turnover: 0.12x
- • Equity Multiplier: 1.56x
- Recent ROE (-42.51%) is above the historical average (-92.00%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.78 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-21.30 Million |
| 2017 | -57.71% | 0.00% | 0.00x | 1.38x | $-39.75 Million |
| 2018 | -154.10% | -951.00% | 0.10x | 1.67x | $-35.44 Million |
| 2019 | -40.87% | -1760.23% | 0.02x | 1.24x | $-65.73 Million |
| 2020 | -85.35% | -2071.03% | 0.02x | 1.69x | $-69.41 Million |
| 2021 | -137.70% | 0.00% | 0.00x | 1.82x | $-95.14 Million |
| 2022 | -126.76% | 0.00% | 0.00x | 2.10x | $-101.27 Million |
| 2023 | -197.98% | 0.00% | 0.00x | 2.88x | $-106.28 Million |
| 2024 | -169.08% | -1464.61% | 0.02x | 6.61x | $-39.66 Million |
| 2025 | -42.51% | -225.55% | 0.12x | 1.56x | $-97.83 Million |
Industry Comparison
This section compares X4 Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $249,490,347
- Average return on equity (ROE) among peers: -108.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| X4 Pharmaceuticals Inc (XFOR) | $155.45 Million | 0.00% | 0.63x | $347.01 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $120.41 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $307.08 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.57 Billion |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $1.25 Million | -621.32% | 5.21x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.34 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $4.73 Billion |
About X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections… Read more